{
  "ticker": "OCC",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02959927",
  "id": "02959927",
  "pages": 4,
  "price_sensitive": true,
  "date": "20250619",
  "time": "0859",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250619/pdf/06kwtfrd4vqcm5.pdf",
  "summary": "- **Key Clinical Study Results**: Remplir\u2122 demonstrates superior nerve regeneration and earlier muscle function recovery compared to standard suture-only repair.  \n- **Market Potential**: Total Addressable Market (TAM) for Remplir exceeds **US$3.5 billion**, with **US$1.8 billion** in currently approved markets.  \n- **US Rollout Progress**: First US sales and surgical use of Remplir imminent; **US$1.6 billion** market targeted.  \n- **Funding Position**: **~A$30 million** cash reserves; company fully funded for global rollout.  \n- **Regulatory Milestones**: EU/UK submission planned for **Q4 CY25**; Canada launch accelerated.  \n\nNo material capital markets actions (e.g., raising, halt) identified. Focus on clinical validation and commercialization.",
  "usage": {
    "prompt_tokens": 2913,
    "completion_tokens": 171,
    "total_tokens": 3084,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-18T23:14:49.303726"
}